Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · IEX Real-Time Price · USD
2.824
+0.054 (1.95%)
At close: May 20, 2024, 2:51 PM
2.870
+0.046 (1.63%)
After-hours: May 20, 2024, 5:51 PM EDT

Company Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.

Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.

Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Lisata Therapeutics, Inc.
Lisata Therapeutics logo
Country United States
Founded 1980
Industry Biotechnology
Sector Healthcare
Employees 25
CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.

Contact Details

Address:
110 Allen Road, Second Floor
Basking Ridge, New Jersey 07920
United States
Phone 908-229-2590
Website lisata.com

Stock Details

Ticker Symbol LSTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000320017
CUSIP Number 128058302
ISIN Number US1280583022
Employer ID 22-2343568
SIC Code 2834

Key Executives

Name Position
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, Chief Executive Officer and Director
Dr. Kristen K. Buck M.D. Executive Vice President of Research & Development and Chief Medical Officer
James Nisco Vice President of Finance and Treasury
Tariq Imam Vice President of Business Development and Operations and Corporate Counsel
Gregory S. Berkin Chief Information Officer
John D. Menditto Vice President of Investor Relations and Corporate Communications
Gail Holler Vice President of Human Resources
Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs

Latest SEC Filings

Date Type Title
May 9, 2024 EFFECT Notice of Effectiveness
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 1, 2024 S-3 Registration statement under Securities Act of 1933
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 17, 2024 8-K Current Report
Mar 28, 2024 ARS Filing
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report